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Abstract
Background The aim of this study was to assess the relative prognostic value of biomarkers to measure the systemic inflamma-
tory response (SIR) and improve prognostic modeling in a cohort of patients undergoing potentially curative surgery for gastric
adenocarcinoma. The hypothesis was that a single SIR biomarker would be associated with the most prognostic value.
Methods Consecutive 331 patients undergoing surgery for gastric cancer between 2004 and 2016 within a regional UK cancer
network were identified. Serummeasurements of hemoglobin, C-reactive protein, albumin, modified Glasgow Prognostic Score,
and differential white cell counts were obtained before surgery, and correlated with histopathological factors (pTNM stage,
differentiation, and vascular invasion) and survival. Primary outcome measures were disease-free (DFS) and overall survival
(OS).
Results Consecutive 331 patients were identified and 291 underwent potentially curative gastrectomy for adenocarcinoma. On
univariable DFS analysis, female gender (p = 0.027), proximal location (p = 0.018), pT stage (p < 0.001), pN stage (p < 0.001),
pTNM stage (p < 0.001), vascular invasion (p < 0.001), poor differentiation (p = 0.001), lymph node ratio (p < 0.001), R1 status
(p < 0.001), platelet count (p = 0.038), and mGPS (p = 0.001) were significantly associated with poor survival. The mGPS was
associated with advanced pT stage (p = 0.001), pTNM stage (p = 0.013), and poor differentiation (p = 0.030). On multivariable
DFS analysis, mGPS [hazard ratio (HR) 2.51, 95% confidence interval (CI) 1.35–4.65, p = 0.011] was the only inflammatory
marker to retain independent significance. Multivariable OS analysis revealed similar findings; mGPS (HR 2.75, (95% CI 1.65–
4.59), p < 0.001).
Conclusion mGPS is an important and only SIR-related prognostic biomarker independently associated with both DFS and OS
in gastric cancer.
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Introduction
The term biomarker originated in the 1950s and has been
defined by the National Institute of Health as a characteristic
that is objectively measured and evaluated as an indicator of
normal biological processes, pathological processes, or phar-
macological responses to a therapeutic intervention.1
Examples include everything from pulse and blood pressure,
through basic biochemistry, to more complex laboratory tests
of blood and other tissues. Globally, gastric cancer is the third
leading cause of cancer-related death, accounting for some
740,000 deaths annually.2 Surgery remains the only
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potentially curative treatment, yet some 40% of patients de-
velop recurrence, and the use of chemotherapy has no firmly
established standard of care. Any reasonable observer there-
fore would recognize that a prime challenge is to identify
biomarkers that may improve prognostic modeling, indepen-
dent of contemporary staging, which may promote new ther-
apeutic targets.
Cancer-related inflammation has been termed the 7th hall-
mark of cancer,3 and the systemic inflammatory response
(SIR) measured using cellular (whole white cell counts, neu-
trophils, lymphocytes, and platelets) and humoral [C-reactive
protein (CRP) and albumin] components. Derivative bio-
markers (neutrophil-lymphocyte ratio (NLR),4 platelet-
lymphocyte ratio (PLR),5 neutrophil-platelet score (NPS),6
and the modified Glasgow prognostic score (mGPS)7,8 have
also been described and reported to be associated with poor
survival in patients undergoing potentially curative surgery. If
the SIR is to be considered a possible therapeutic target, then a
single marker is desirable, that is sensitive, specific, robust,
accurate, and reproducible. Reports regarding biomarker sig-
nificance, in minimizing confounding variables, have only
included common clinicopathological factors in multivariable
regression models,4,6,9 and no study has examined rigorously
the relative prognostic significance of the SIR’s individual
components and derivative markers.
The aim of this study was to determine if a single biomark-
er of the SIR was independently associated with survival, in
patients undergoing potentially curative gastrectomy for can-
cer. The hypothesis was that a composite biomarker of the SIR
would have significant optimum prognostic value, indepen-
dent of histopathological TNM stage, and other SIR markers
on multivariable regression modeling. The setting was a re-
gional UK cancer network serving a population of 1.8 million.
Methods
Patients
In order to test the hypotheses proposed in this study, a single
cohort was developed and included patients with radiological
TNM stage I to III, who following staging were deemed to
have potentially resectable gastric cancer between January
2004 and December 2016. All patients were managed by a
multidisciplinary team of specialists with an interest in gastric
cancer and included surgeons, oncologists, radiologists, anes-
thetists, and pathologists. Preoperative staging involved com-
puted tomography (CT) of the thorax, abdomen, and pelvis as
well as a staging laparoscopy of the peritoneal cavity when
appropriate, in order to facilitate individually patient tailored
management plans. Patients who underwent endoscopic re-
section and Siewert II cancers that were managed as oesoph-
ageal cancers were not included in the study.
Selective use of neoadjuvant chemotherapy was adopted
following publication of the Medical Research Council
Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial 10
in the latter part of the study and was prescribed to 45 patients
with minimal comorbidities who were deemed to have rela-
tively advanced disease and would benefit from down-staging
of the tumor prior to surgery. Chemotherapy was administered
for 3 or 4 cycles preoperatively and postoperatively. Each
cycle consisted of epirubicin (50 mg/m2) by intravenous bo-
lus, cisplatin (60 mg/m2) as a 4-h infusion on day one and 5-
fluorouracil (200 mg/m2/day) daily by a continuous intrave-
nous infusion.
The type of surgery for gastric cancer was determined by
the anatomical location of the tumor; subtotal gastrectomy
was performed in patients with antral tumors and total gastrec-
tomy was performed in patients with tumors of the cardia
(Siewert type III), body, and linitis plastic. A modified extend-
ed D2 lymphadenectomy (preserving pancreas and spleen
where possible) was performed and the operative approach
was open in all cases.
Ethical approval was sought, but the chair of Cardiff &
Value University Health Board ethics committee confirmed
that individual patient consent was not required to report clin-
ical outcomes alone, and no formal approval was necessary.
Clinicopathological Characteristics
Tumors were staged using the seventh edition of the
AJCC/UICC-TNM staging system. Pathological factors were
recorded from pathology reports issued at the time of surgery
and included tumor differentiation, vascular invasion, margin
status, and the number of lymph nodes with and without me-
tastasis. The metastatic to normal lymph node ratio (LNR)
was calculated by dividing the number of lymph nodes con-
taining metastatic carcinoma to the total number of lymph
nodes identified. The LNR was then categorized as low risk
< 0.25 and high risk > 0.50 within the TNM stage III.11
Routine laboratory measurements of whole white cell count,
neutrophil count, lymphocyte count, platelet counts, CRP, and
albumin were taken on the day prior to surgery. Derivate mea-
surements of systemic inflammation consisted of the NLR,
NPS, PLR, and the mGPS were calculated. The NLR and
PLR were constructed by calculated the neutrophil to lympho-
cyte ratio and the platelet to lymphocyte ratio, respectively.
These derivative measurements were then dichotomized into
low and high groups by 5.5 for NLR and 150 for PLR.11 The
NPS was constructed by grouping patients into three groups; 0
for patients with both normal neutrophil (≤ 7.5 × 109/L) and
platelet counts (≤ 400 × 109/L), 1 for patients with either a high
neutrophil (> 7.5 × 109/L) or platelet count (> 400 × 109/L), and
2 for patients with both high neutrophil and platelet counts. The
mGPS was constructed using CRP and albumin. Patients with
normal serum levels of CRP (≤ 10 mg/L) and albumin (≥ 35 g/
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L) were given a score of 0. Patients with a raised serum CRP
(> 10 mg/L) and normal serum albumin were given a score of 1
and patients with a raised serum CRP and low serum albumin
(< 35 g/L) were given a score of 2.12
Patients were followed up at regular intervals of 3 months
for the first year and 6 months thereafter. In the event that
patients developed symptoms suggestive of recurrent disease,
investigations were undertaken sooner. Follow-up surveillance
was conducted for 5 years or until death whichever was sooner.
Overall survival was calculated from time of diagnosis to the
date of death. Disease-free survival wasmeasured from the date
of surgery until the date of recurrence or date of censoring. The
median follow-up was 60 months (range 6 to 60), with 255
patients (77%) followed up for 5 years or until death. No pa-
tients were lost to follow-up. Death certification was obtained
from the Office for National Statistics via Cancer Network
Information System Cymru (CaNISC). Patterns of recurrence
were defined as locoregional, distant (metastatic), or both
locoregional and distant, when bothwere diagnosed at the same
time. The time of recurrence was taken as the date of the con-
firmatory investigation.
Statistical Analysis
Justification of Sample Size
Sample size calculations were based on a prestudy literature
survey of (CRUK cancers statistics),13 which indicated that
the baseline 5-year survival rate of patients diagnosed with
stage I gastric cancer was expected to be 80%, compared with
60% in patients with stage II gastric cancer, and a 15% differ-
ence in survival would be a realistic expectation. Thus, a min-
imum of 276 patients were to be studied, providing 80% pow-
er to detect such a difference with p < 0.05.
Methods of Data Analysis
Grouped data were expressed as median (range) and nonpara-
metric methods used throughout. Patient demographics were
analyzed between the treatment modalities by means of χ2 or
nonparametric tests, including Mann-Whitney U test. These
tests were also employed in the analysis of disease recurrence
and time to recurrence for the treatment groups. Disease-free
survival for all patients was calculated by measuring the inter-
val from a landmark time of 6months after diagnosis to the date
of recurrence. This approach was adopted in previous random-
ized trials,10–14 to allow for the variable interval to surgery
following diagnosis, depending on whether neoadjuvant thera-
pywas prescribed. As in these trials, events resulting in a failure
to complete curative treatment, such as not proceeding to sur-
gery, open and close laparotomy, palliative resection, in-
hospital mortality, and disease progression during neoadjuvant
chemotherapy, were assumed to have occurred at this landmark
time, to maintain the intention-to-treat analysis. Overall surviv-
al was measured from the date of diagnosis. Cumulative sur-
vival was calculated according to the method of Kaplan and
Meier; differences between groups were analyzed with the log-
rank test. Univariable analyses examining factors influencing
survival were examined initially by the life table method of
Kaplan and Meier, and those with associations found to be
significant (p < 0.010) were retained in a Cox proportional
hazards model using forward conditional methodology to as-
sess the prognostic value of individual variables. All statistical
analysis was performed in SPSS® (IBM® SPSS® Statistics
v23.0.0.0, IBM Corporation, Armonk, New York, USA) with
extension R.
Results
Patients, Clinicopathological Factors, and Features
Associated with Nonresectability
In total, 331 patients were identified who underwent surgery for
gastric cancer. Unfortunately, 41 (12.3%) patients were deemed
not to have resectable tumors because of local invasion and
those at risk of obstruction underwent a palliative bypass. The
remainder, 291 patients, underwent potentially curative modi-
fied D2 gastrectomy. The patient cohort undergoing palliative
surgery had a higher proportion of males (p = 0.002), raised
serum CRP measurements (p = 0.003), hypoalbuminaemia
(p = 0.024), higher mGPS (p = 0.001), and a fewer patients
had undergone neoadjuvant chemotherapy (p = 0.024, supple-
mentary table 1). On multivariable binary logistical regression
analysis of significantly associated factors on univariable anal-
ysis, only male gender (odds ratio (OR) 4.66 (95% confidence
interval (95% CI 1.60–13.58) p = 0.005), and the mGPS (OR
1.92 (1.27–2.88) p = 0.002) were independently associated
with nonresectability. The area under the curve (AUC) for male
gender was 0.62 (95% CI 0.54–0.70, p = 0.015) and the AUC
for mGPS was 0.61 (95% CI 0.51–0.71, p = 0.021).
Resection Cohort Demographics
The complete baseline characteristics of all clinicopathologi-
cal variables studied can be found in Tables 1 and 2. The
median age for patients undergoing resection was 69 years
(inter-quartile range (IQR) 55–83) with the majority (42.1%)
being between 65 and 75 years of age (Table 2). The majority
of patients were male (66.7%), had distal cancer (45.0%), and
were lymph node positive (55.0%). Neoadjuvant chemother-
apy was prescribed to 45 patients (15.5%), and 61 patients
(21%) received postoperative adjuvant chemotherapy
(Table 1). During follow-up, 81 patients (27.8%) developed
cancer recurrence and 109 patients (37.5%) died. Median
follow-up of survivors was 60 (range 6–60) months.
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Relationships Between Clinicopathological Factors
and Disease-free Survival
The relationship between disease-free survival and all stud-
ied factors can be found in supplementary table 2. On
univariable analysis, female gender, proximal location,
advancing T stage, advancing N stage, advancing TNM
stage, poor differentiation, vascular invasion, advancing
lymph node ratio, R1 status, higher platelet count, raised
CRP, and advancing mGPS (Fig. 1) were all associated with
poor disease-free survival (p < 0.005) (Table 3). On multi-
variable analysis, only TNM stage (when compared with
Table 1 The relationship between tumor-related factors, overall survival, and disease-free survival in patients undergoing potentially curative resection
for gastric cancer
Clinicopathological variables Frequency n (%) Disease-free survival p value Overall survival p value
5-year survival rate (%) 5-year survival rate (%)
Tumor site
Proximal 95 (32.6) 36.1 0.001 39.3 0.002
Body 65 (22.3) 65.9 65.9
Distal 131 (45.0) 62.6 65.9
< 15 157 (54.0) 56.0 57.8
T stage
1 66 (23.0) 89.6 < 0.001 89.6 < 0.001
2 27 (9.3) 78.6 85.7
3 105 (36.1) 49.3 52.2
4 92 (31.6) 30.8 33.8
N stage
0 131 (45.0) 73.7 < 0.001 75.8 < 0.001
1 63 (21.6) 55.6 58.3
2 52 (17.9) 27.3 30.3
3 45 (15.5) 21.4 25.0
Tumor stage
I 79 (27.1) 90.4 < 0.001 90.4 < 0.001
II 92 (31.6) 59.4 65.2
III 120 (41.2) 25.0 26.4
Differentiation
Well/moderate 150 (51.5) 62.3 0.029 65.1 0.022
Poor 141 (48.5) 46.7 48.9
Vascular invasion
No 168 (57.2) 65.9 < 0.001 68.2 < 0.001
Yes 123 (42.3) 32.8 35.9
Lymph node ratio
0 131 (45.0) 73.7 < 0.001 75.8 < 0.001
0.01–0.24 75 (25.8) 53.2 55.3
0.25–0.49 54 (18.6) 20.0 23.3
≥ 0.50 31 (10.7) 20.0 25.0
Lymph node sample
≥ 15 134 (46.0) 54.0 0.786 57.5 0.963
R status
0 246 (84.5) 61.0 < 0.001 64.0 < 0.001
1 45 (15.5) 12.5 12.5
Adjuvant chemotherapy
No 230 (79.0) 69.9% 0.725 60.8% 0.147
Yes 61 (21.0) 66.7% 46.7%
Neoadjuvant therapy
No 246 (84.5) 56.3 0.338 59.1 0.227
Yes 45 (15.5) 45.0 45.0
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stage I, stage II hazard ratio (HR) 9.08 (2.13–38.67)
p < 0.001 and stage III HR 15.83 (3.73–67.11) p < 0.001),
vascular invasion (HR 1.70 (1.07–2.70) p = 0.024), R1 sta-
tus (HR 2.50 (1.51–14.14) p = 0.002), and advancing mGPS
(when compared with mGPS = 0, mGPS = 2 (HR 2.51
(1.35–4.65) p = 0.020) were independently associated with
poor disease-free survival (Table 3). The 5-year disease-free
survival was 51.9% for patients with a mGPS = 0, 34.8% for
Table 2 The relationship between patient-related factors, overall survival, and disease-free survival in patients undergoing potentially curative
resection for gastric cancer
Clinicopathological variables Frequency n (%) Disease-free survival p value Overall survival p value
5-year survival rate (%) 5-year survival rate (%)
Age (years)
< 65 99 (34.0) 62.1 0.053 51.5 0.714
65–75 121 (41.6) 67.5 45.8
> 75 years 71 (24.4) 83.0 44.7
Sex
Female 97 (33.3) 61.5 0.093 38.5 0.076
Male 194 (66.7) 73.3 51.9
White cell count
Low 205 (70.4) 68.6 0.938 46.7 0.823
Normal 63 (21.6) 71.1 51.1
High 23 (7.9) 71.4 42.9
Neutrophil count
Low 264 (90.7) 68.7 0.507 46.4 0.326
High 27 (9.3) 76.5 58.8
Lymphocyte count
Low 27 (9.3) 70.6 0.908 29.4 0.236
Normal 250 (85.9) 69.6 49.7
High 14 (4.8) 62.5 37.5
Platelet count
Low 260 (89.3) 71.3 0.109 49.6 0.119
High 31 (10.7) 54.5 31.8
C-reactive protein
Normal 231 (79.4) 73.4 0.020 51.9 0.016
High 60 (20.6) 54.8 31.0
Albumin
Normal 219 (75.3) 70.1 0.680 49.7 0.209
Low 72 (24.7) 66.7 38.5
Derivative markers
Neutrophil-lymphocyte
Ratio
Low 261 (89.7) 70.7 0.266 47.1 0.800
High 30 (10.3) 59.1 50.0
Neutrophil-platelet score
Low 239 (82.1) 71.4 0.075 49.7 0.011
Intermediate 46 (15.8) 54.8 29.0
High 6 (2.1) 100.0 100.0
Platelet-lymphocyte
Ratio
Low 143 (49.1) 73.5 0.215 54.1 0.063
High 148 (50.9) 65.3 40.8
Modified Glasgow Prognostic Score
Low 231 (79.4) 73.4 0.044 51.9 0.015
Intermediate 31 (10.7) 52.2 34.8
High 29 (10.0) 57.9 26.3
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patients with a mGPS = 1, and 26.3% for patients with a
mGPS = 2 (Table 2).
Relationships Between Clinicopathological Factors
and Overall Survival
The relationship between overall survival and all studied fac-
tors can be found in supplementary Table 2. On univariable
analysis, proximal location, advancing pT stage, advancing
pN stage, advancing pTNM stage, poor differentiation, vascu-
lar invasion, advancing lymph node ratio, R1 status, raised
CRP, and advancing mGPS (Fig. 1) were all associated with
poor overall survival (p < 0.05) (Table 3). On multivariable
analysis, only pT stage (when compared with T1, T3 HR 1.87
(1.03–3.41) and pT4HR 3.02 (1.66–5.49) p < 0.001), vascular
invasion (HR 2.04 (1.39–2.97) p < 0.001), R1 status (HR 2.18
(1.40–3.40) p < 0.001), and advancing mGPS (when com-
pared with mGPS = 0, mGPS = 1 (HR 2.06 (1.25–3.39) and
mGPS = 2 (HR 2.75 (1.65–4.59), p < 0.001) were indepen-
dently associated with poor overall survival (Table 3). The
number of events per variable was 12.1.
The Relationship Between Clinicopathological Factors
and the mGPS
The relationship between mGPS and clinicopathological fac-
tors is shown in Table 4. The mGPS was associated with
advancing pT stage, advancing pTNM stage, poor differenti-
ation, lower proportion of neoadjuvant treatments, raised
white cell count, raised neutrophil count, raised platelet count,
raised NLR, raised NPS, and a raised PLR (all p < 0.05)
(Table 4).
Discussion
The principal finding of this study was that the modified
Glasgow prognostic score was the only inflammatory-based
prognostic biomarker in a cohort of UK patients with gastric
cancer, supporting the primary hypothesis. No fewer than one
in five patients had raised markers of SIR, and some 1 in 10
the maximum SIR score. Patients with mGPS scores of zero
experienced median DFS and OS, on average 15 and
16 months, respectively, better than patients with mGPS of
two. Compared with a mGPS of zero, patients with a mGPS
of two were nearly 3 times more likely to have nonresectable
disease at laparotomy, 78% more likely to have T4 disease,
30% more likely to have TNM stage III disease, and be asso-
ciated with both poor disease-free and overall survival.
Similarly, patients with mGPS scores of zero experienced a
5-year DFS and OS of 80 and 52%, eight and twofold better
than patients with mGPS scores of two. Sensitivity and spec-
ificity for patients with a mGPS of zero and two were 26 and
93% for DFS, and 2% and 94% for OS.
The modified Glasgow prognostic score has been associat-
ed with poor survival in a spectrum of anatomical cancer sites
including colorectal,12 lung,7 breast,15 prostate,16 and gastric
cancer.17 Based on the mGPS as a marker of inflammation,
20% of patients undergoing resection for gastric cancer had
evidence of systemic inflammation on preoperative blood
analysis. This compares with 36.5% of patients in colorectal
cancer.18 Park et al. reported that 63.8, 20.7, and 15.5% of
colorectal cancer patients had mGPS scores of zero, one, and
two respectively, with associated a respective 5-year survival
of 70% (mGPS zero), 60% (mGPS one), and 46% (mGPS
two). The observation of a stepwise 10–15% difference in a
5-year survival relative to each mGPS subgroup was mirrored
in this study, although the overall survival of mGPS zero
p=0.001 p<0.001
No. at
risk 
0 231 195 157 130 118 105 91 
1 31 25  18 14 13 12 11 
2 29 19 12 9 9 6 4 
No. at 
risk 
0 231 205 176 136 120 107 96 
1 31 24 18 15 13 13 12 
2 29 20 14 11 9 6 5 
a b
Fig. 1 The relationship between mGPS and survival; disease-free a and overall survival b
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patients was 50%, arguably reflecting the inherent aggressive
nature of gastric cancer. Although the relationship between
mGPS and gastric cancer survival has been reported before,
this is the first report to highlight the superior prognostic value
of the mGPS when compared with all markers of inflamma-
tion readily available to clinicians. The conceptual role of the
host and cancer-related factors in predicting survival is not
new. Roxburgh et al. 11 and Dutta et al. 9 examined host and
Table 3 Univariable and multivariable analysis of clinicopathological factors and serum inflammatory markers; disease-free and overall survival
Univariable p value Multivariable p value Univariable p value Multivariable p value
Disease-free survival Overall survival
Hazard ratio (95% CI) Hazard ratio
(95% CI)
Hazard ratio (95% CI) Hazard ratio
(95% CI)
Sex
Female 1 0.027 0.120
Male 0.61 (0.39–0.95)
Tumor site
Proximal 1 0.018 0.551 1 0.004 0.110
Body 0.42 (0.22–0.80) 0.48 (0.29–0.78)
Distal 0.62 (0.39–1.00) 0.61 (0.42–0.89)
T stage
1 1 < 0.001 0.518 1 < 0.001 1 < 0.001
2 5.79 (1.06–31.59) 1.35 (0.55–3.32) 0.76 (0.29–1.94)
3 14.89 (3.58–61.83) 2.85 (1.60–5.08) 1.87 (1.03–3.41)
4 22.28 (5.37–92.40) 4.78 (2.71–8.45) 3.02 (1.66–5.49)
N stage
0 1 < 0.001 0.369 1 < 0.001 0.614
1 5.15 (2.69–9.89) 1.97 (1.24–3.14)
2 5.02 (2.51–10.03) 2.55 (1.59–4.10)
3 8.67 (4.41–17.04) 3.63 (2.26–5.84)
TNM stage
I 1 < 0.001 1 < 0.001 1 < 0.001 0.567
II 12.51 (2.97–52.72) 9.08 (2.13–38.67) 2.43 (1.38–4.26)
III 28.80 (7.00–118.45) 15.83 (3.73–67.11) 5.05 (2.96–8.61)
Differentiation
Well/moderate 1 0.001 0.352 1 0.006 0.577
Poor 2.20 (1.41–3.45) 1.62 (1.15–2.28)
Vascular invasion
No 1 < 0.001 1 0.024 1 < 0.001 1 < 0.001
Yes 2.89 (1.86–4.50) 1.70 (1.07–2.70) 2.43 (1.72–3.43) 2.04 (1.39–2.97)
Lymph node ratio
0 1 <0.001 0.448 1 < 0.001 0.444
0.01–0.24 4.54 (2.39–8.62) 1.88 (1.20–2.93)
0.25–0.49 6.84 (3.50–13.37) 3.13 (1.96–4.99)
≥ 0.50 8.83 (4.29–18.17) 3.75 (2.24–6.30)
R status
0 1 < 0.001 1 0.002 1 < 0.001 1 < 0.001
1 4.21 (2.73–6.49) 2.50 (1.51–4.14) 2.78 (1.89–4.10) 2.18 (1.40–3.40)
Platelet count
Low 1 0.038 0.505
High 1.87 (1.03–3.39)
Modified Glasgow Prognostic Score
Low 1 0.001 1 0.011 1 < 0.001 1 < 0.001
Intermediate 1.98 (1.08–3.63) 1.76 (0.96–3.25) 1.91 (1.17–3.08) 2.06 (1.25–3.39)
High 2.86 (1.56–5.24) 2.51 (1.35–4.65) 2.79 (1.72–4.54) 2.75 (1.65–4.59)
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Table 4 The relationship
between the modified Glasgow
Prognostic Score and
clinicopathological factors in
patients undergoing potentially
curative resection for gastric
cancer
Clinicopathological factors mGPS = 0 mGPS = 1 mGPS = 2 p value
Age (years)
< 65 78 (33.8%) 11 (35.5%) 10 (34.5%) 0.885
65–75 94 (40.7%) 13 (41.9%) 14 (48.3%)
> 75 years 59 (25.5%) 7 (22.6%) 5 (17.2%)
Sex
Female 78 (33.8%) 9 (29.0%) 10 (34.5%) 0.863
Male 153 (66.2%) 22 (71.0%) 19 (65.5%)
Tumor site
Proximal 76 (32.9%) 8 (25.8%) 11 (37.9%) 0.697
Body 54 (23.4%) 7 (22.6%) 4 (13.8%)
Distal 101 (43.7%) 16 (51.6%) 14 (48.3%)
T stage
1 63 (27.3%) 3 (9.7%) 1 (3.4%) 0.001
2 20 (8.7%) 4 (12.9%) 3 (10.3%)
3 81 (35.1%) 14 (45.2%) 10 (34.5%)
4 67 (29.0%) 10 (32.3%) 15 (51.7%)
N stage
0 107 (46.3%) 12 (38.7%) 12 (41.4%) 0.471
1 48 (20.8%) 8 (25.8%) 7 (24.3%)
2 45 (19.5%) 4 (12.9%) 3 (10.3%)
3 31 (13.4%) 7 (22.6%) 7 (24.1)
Tumor stage
I 73 (31.6%) 4 (12.9%) 2 (6.9%) 0.013
II 66 (28.6%) 14 (45.2%) 12 (41.4%)
III 92 (39.8%) 13 (41.9%) 15 (51.7%)
Differentiation
Well/moderate 127 (55.0%) 12 (38.7%) 11 (37.9%) 0.030
Poor 104 (45.0%) 19 (61.3%) 18 (62.1%)
Vascular invasion
No 135 (58.4%) 21 (67.7%) 12 (41.4%) 0.105
Yes 96 (41.6%) 10 (32.3%) 17 (58.6%)
Lymph node ratio
0 107 (46.3%) 12 (38.7%) 12 (41.4%) 0.196
0.01–0.24 57 (24.7%) 10 (32.3%) 8 (27.6%)
0.25–0.49 49 (21.2%) 2 (6.5%) 3 (10.3%)
≥ 50 18 (7.8%) 7 (22.6%) 6 (20.7%)
Lymph node sample
≥ 15 107 (46.3%) 11 (35.5%) 16 (55.2%) 0.306
< 15 124 (53.7%) 20 (64.5%) 13 (44.8%)
R status
0 199 (86.1%) 26 (83.9%) 21 (72.4%) 0.068
1 32 (13.9%) 5 (16.1%) 8 (27.6%)
Adjuvant chemotherapy
No 117 (76.6%) 27 (87.1%) 26 (89.7%) 0.052
Yes 54 (23.4%) 4 (12.9%) 3 (10.3%)
Neoadjuvant therapy
No 176 (76.2%) 27 (87.1%) 28 (96.6%) 0.020
Yes 55 (23.8%) 4 (12.9%) 1 (3.4%)
White cell count
Low 172 (74.5%) 23 (74.2%) 10 (34.5%) 0.002
Normal 41 (17.7%) 7 (22.6%) 15 (51.7%)
High 18 (7.8%) 1 (3.2%) 4 (13.8%)
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cancer factors related to survival in colorectal and gastric can-
cer, respectively. Both reported that systemic inflammation
was an important predictor of survival independent of stage.
This study builds on this work by including all of the clinically
available inflammation and pathological factors in a more
comprehensive multivariable model.
There is a now an established evidence base detailing the
poor prognosis associated with the presence of a preoperative
SIR. The findings of this study support the role of inflamma-
tion in tumor progression and metastasis. The mechanism of
how the SIR exerts an adverse influence on survival is unclear,
but is likely part of a complex biosystem involving cellular
signaling and genetic aberrations, resulting in tumor growth,
tissue remodeling, angiogenesis, and dysregulation of the
innate/adaptive immune responses. It is possible that the poor
prognoses associated with SIR is not based on local disease
progression alone, and the finding that SIR was also associat-
ed with the development of metastases, independent of TNM
stage, supports an interaction between tumor and host.
Understanding the underlying physiological mechanisms
would raise the potential of therapeutic targets and further
work is needed in this regard.
It is nowwell-established that the SIR offers valuable prog-
nostic information. Yet, if the SIR and specifically the mGPS
is to be incorporated into a modified TNM staging system,
then it also needs to offer predictive value. Biomarker inclu-
sion into the management of breast cancer was driven by the
identification of adjuvant therapies for higher-risk patients.
Apart from Herceptin treatment for advanced gastric cancer,
the principal adjuvant treatment is cytotoxic chemotherapy. If
the mGPS is to identify patients that may benefit from chemo-
therapy, then evidence of potential response is required.
Unfortunately, evidence from the arena of colorectal cancer
suggests that patients with a SIR experienced poorer outcomes
when undergoing neoadjuvant,19 or adjuvant chemotherapy 20
when compared with controls. Moreover, based on histologi-
cal assessment, the mGPS in rectal cancer patients was asso-
ciated with a greater and significant likelihood of nonresponse
to neoadjuvant chemotherapy.21 Although, the mGPS has
been associated with poorer survival in patients undergoing
chemotherapy for gastric cancer,22 its role in predicting re-
sponse to neoadjuvant therapy is unknown. Given the associ-
ations between systemic inflammation and poor response to
chemotherapy, it is unlikely that these patients will derive
benefit from adjuvant chemotherapy following potentially cu-
rative resection suggesting that alternative therapeutic modal-
ities are needed. The phase III, double-blinded, placebo-
controlled randomized trial assessing the effects of aspirin
on disease recurrence and survival after primary therapy in
common nonmetastatic solid tumors (Add-Aspirin) com-
menced recruiting in October 2015.23 Although this study
should offer valuable information on whether aspirin might
benefit and be offered to all patients undergoing potentially
curative gastrectomy, it is possible that only patients with a
SIR will likely respond. Similar to other adjuvant treatments
such as Herceptin and Cetuximab, patient selection will be
crucial and the mGPS has the potential to be a valuable pre-
dictive biomarker in this setting.
Table 4 (continued)
Clinicopathological factors mGPS = 0 mGPS = 1 mGPS = 2 p value
Neutrophil count
Low 216 (92.6%) 31 (100.0%) 19 (65.5%) < 0.001
High 17 (7.4%) 0 (0.0%) 10 (34.5%)
Lymphocyte count
Low 17 (7.4%) 5 (16.1%) 5 (17.2%) 0.160
Normal 201 (87.0%) 26 (83.9%) 23 (79.3%)
High 13 (5.6%) 0 (0.0%) 1 (3.4%)
Platelet count
Low 210 (90.9%) 28 (90.3%) 22 (75.9%) 0.046
High 21 (9.1%) 3 (9.7%) 7 (24.1%)
Neutrophil-lymphocyte ratio
Low 219 (94.8%) 27 (87.1%) 15 (51.7%) < 0.001
High 12 (5.2%) 4 (12.9%) 14 (48.3%)
Neutrophil-platelet score
Low 197 (85.3%) 28 (90.3%) 14 (48.3%) < 0.001
Intermediate 30 (13.0%) 3 (9.3%) 12 (41.4%)
High 4 (1.7%) 0 (0.0%) 3 (10.0%)
Platelet-lymphocyte ratio
Low 128 (55.4%) 7 (22.6%) 8 (27.6%) < 0.001
High 103 (44.6%) 24 (77.4%) 21 (72.4%)
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There are a number of inherent limitations and potential
criticisms of this study. Cohort sample size was modest and
the study was powered based on a 15% difference in survival,
subanalysis related to tumor stage was therefore not possible.
Data related to patients’ race, body mass indices, and detailed
comorbidity was not collected in the prospective database, and
was therefore not available for analysis as confounding fac-
tors, but is worthy of further study. Validating these results in
an appropriately powered cohort for subanalysis related to
stage II and III disease may help integrate the mGPS into a
modified TNM staging system. The patient cohort studied is a
selected group (most had undergone a potentially curative R0
gastrectomy) and were certainly not representative of all pa-
tients with gastric cancer; indeed, only approximately one
third of the patients in South Wales undergo potentially cura-
tive resection.24 In contrast, the study has several strengths,
benefiting from robust follow-up data with accurate causes
and dates of death obtained from the office of national statis-
tics; over 75%were followed up for at least 5 years or death. A
NHS laboratory using standardized techniques performed the
serum measurements, and therefore reproducing these results
is not anticipated to be problematic. Moreover, the patients
were recruited from a consecutive series of patients diagnosed
with gastric cancer, from a single UK geographical region,
and all had been treated by the same multidisciplinary team
and group of specialist surgeons, using a standardized staging
algorithm and operative technique, with extensive audited and
published quality control.
In conclusion, the mGPS was the only inflammatory-based
prognostic biomarker to be associated with poorer OS and
DFS in patients undergoing potentially curative resection for
gastric cancer, and was independent of pathological stage. In
light of emerging evidence that SIR predicts poor survival and
nonresponse in patients undergoing perioperative chemother-
apy, other therapeutic modalities and options are desirable.
These findings suggest that the SIR may offer an original
and novel therapeutic target for patients more susceptible to
cancer recurrence, and the modifiedGlasgow Prognostic Score
may represent the most promising biomarker available for
patient tailored holistic antiinflammatory treatment.
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